Showcasing Ontario's High Potential Companies: Niagara Emerging Health Sciences Company Forum - Part 2

Showcasing Ontario's High Potential Companies: Niagara Emerging Health Sciences Company Forum - Part 2

This week, in Part 2 of a blog that began last week, we review the Niagara Emerging Health Science Company Forum, held in Niagara-on-the-Lake on Feb 1-2, 2018.

The forum brought together CEOs and senior executives from high potential Canadian health science companies with senior leadership from American investors and strategics in beautiful Niagara-on-the-Lake for two days of panel presentations, executive roundtables, and networking dinners.

OBIO CAAP Company: ImmunoBiochem Corporation Enters Into Collaboration & Option Agreement with Advanced Proteome Therapeutics

Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and ImmunoBiochem Corporation, today announced entering into a Collaboration and Option agreement to develop superior antibody-drug conjugates. The companies will evaluate the prospect of combining ImmunoBiochem’s proprietary antibody and APC’s site-selective conjugation technology to produce ADCs with superior properties, targeting triple-negative breast cancer.

OBIO CAAP Company: Biotagenics Partners with University of Ottawa and CHEO on $9.1 Million Project with Genome Canada to Develop Therapies for Inflammatory Bowel Disease

Toronto – Biotagenics Inc., a microbiome-based platform company developing novel therapeutics and diagnostics is the industrial collaborator on a $9.1 million CAD ($7.4 million USD) project led by academic collaborators at University of Ottawa and Children’s Hospital of Eastern Ontario (CHEO) to study the clinical application of microbiome-based precision medicine in pediatric inflammatory bowel disease (IBD).

OBIO CAAP Company: Mariner Endosurgery Receives Health Canada Investigational Testing Approval for LaparoGuard Technology

Mariner Endosurgery Inc., an innovative Canadian medical device company leading commercialization of computer-assisted medical devices for laparoscopic surgeries, announced today that it has received Investigational Testing Approval (ITA) from Health Canada.  Receipt of the ITA enables the company to initiate clinical testing of Mariner’s LaparoGuard computer-assisted surgery platform which is planned to begin February 2018 at Hamilton General Hospital.  Dr. Niv Sne, trauma surgeon proficient in advanced laparoscopic cases with Hamilton Health Sciences and Associate Professor of Surgery at McMaster University is the principal investigator for the initial studies.

CAAP Company: Self Care Catalysts awarded IDC Innovator

International Data Corporation (IDC) Canada released an IDC Innovators report recognizing Canadian personal health record startups with revenue under C$100 million. CAAP Company Self Care Catalysts were 1 of 4  companies selected evaluated on their ability to offer an innovative new technology, a ground-breaking approach to an existing issue, and/or an interesting new business model in a specific market.

OBIO Pre-CAAP Company: Proteocyte Announces Changes to Board of Directors for 2018

Proteocyte Diagnostics, a company that has designed a platform technology to predict your risk of developing cancer, announces the restructuring and expansion of the Board of Directors with the addition of James Appleyard, Laurence Hicks,  Peter G. Schulam and Carlo Sistilli. Proteocyte is also pleased to announce that Robert Lawrie, the Chair of the Canadian Cancer Society, has agreed to join the Board.